168 related articles for article (PubMed ID: 29777005)
21. Locoregional and radioisotopic targeted treatment of neuroendocrine tumours.
Hendlisz A; Flamen P; Van den Eynde M; Borbath I; Demetter P; Demolin G; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsemo E; Van Hootegem P; Van Laethem JL; Verslype C; Delaunoit T
Acta Gastroenterol Belg; 2009; 72(1):44-8. PubMed ID: 19402371
[TBL] [Abstract][Full Text] [Related]
22. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?
Önner H; Abdülrezzak Ü; Tutuş A
Nucl Med Commun; 2020 Oct; 41(10):1034-1039. PubMed ID: 32516240
[TBL] [Abstract][Full Text] [Related]
23. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours.
Nwosu AC; Jones L; Vora J; Poston GJ; Vinjamuri S; Pritchard DM
Br J Cancer; 2008 Mar; 98(6):1053-8. PubMed ID: 18283308
[TBL] [Abstract][Full Text] [Related]
25. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
27. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
28. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
[No Abstract] [Full Text] [Related]
29. Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
Sze WC; Grossman AB; Goddard I; Amendra D; Shieh SC; Plowman PN; Drake WM; Akker SA; Druce MR
Br J Cancer; 2013 Aug; 109(3):565-72. PubMed ID: 23860527
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
31. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
32. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D
Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668
[TBL] [Abstract][Full Text] [Related]
33. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.
Bomanji JB; Wong W; Gaze MN; Cassoni A; Waddington W; Solano J; Ell PJ
Clin Oncol (R Coll Radiol); 2003 Jun; 15(4):193-8. PubMed ID: 12846498
[TBL] [Abstract][Full Text] [Related]
34. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
Navalkissoor S; Alhashimi DM; Quigley AM; Caplin ME; Buscombe JR
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):904-12. PubMed ID: 20016892
[TBL] [Abstract][Full Text] [Related]
36. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
37. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
38. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
39. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
Jimenez C; Núñez R; Wendt R
Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):162-169. PubMed ID: 32250976
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.
Katona BW; Roccaro GA; Soulen MC; Yang YX; Bennett BJ; Riff BP; Glynn RA; Wild D; Nicolas GP; Pryma DA; Teitelbaum UR; Metz DC
Pancreas; 2017 Oct; 46(9):1121-1126. PubMed ID: 28902781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
